GPC Satraplatin Prostate Cancer Rolling NDA To Complete In Second Half Of 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm seeks second-line indication for the oral platinum compound following completion of accrual in pivotal SPARC trial.